Biomea Fusion, Inc. (BMEA) — SEC Filings
Biomea Fusion, Inc. (BMEA) — 38 SEC filings. Latest: 10-Q (Nov 4, 2025). Includes 19 8-K, 6 10-Q, 6 SC 13G/A.
View Biomea Fusion, Inc. on SEC EDGAR
Overview
Biomea Fusion, Inc. (BMEA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 4, 2025: Biomea Fusion, Inc. (BMEA) reported a net loss of $16.407 million for the three months ended September 30, 2025, a significant improvement from the $32.787 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $66.409 million, down from $109.124
Sentiment Summary
Across 38 filings, the sentiment breakdown is: 2 bullish, 34 neutral, 2 mixed. The dominant filing sentiment for Biomea Fusion, Inc. is neutral.
Filing Type Overview
Biomea Fusion, Inc. (BMEA) has filed 6 10-Q, 19 8-K, 2 DEF 14A, 2 10-K, 6 SC 13G/A, 3 SC 13G with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (38)
Risk Profile
Risk Assessment: Of BMEA's 31 recent filings, 2 were flagged as high-risk, 10 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$16.407M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $46.642M |
| Operating Margin | N/A |
| Total Assets | $55.187M |
| Total Debt | $39.568M |
Key Executives
- Dr. Michael J. Kelly
- Thomas L. Jenkins
- Dr. David R. Parkinson
- Thomas Butler
- Michael J. M. Hitchcock, Ph.D.
- Rainer M. Erdtmann
- Abigail P. Johnson
- December 31, 2023
Industry Context
Biomea Fusion operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel therapies. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success hinges on scientific innovation, clinical trial outcomes, and securing substantial funding to navigate these challenges.
Top Tags
financials (6) · 8-k (5) · sec-filing (5) · 8-K (4) · filing (4) · 10-Q (4) · institutional-ownership (4) · corporate-governance (3) · regulatory-filing (3) · passive-investment (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $16.407M | Decreased from $32.787M in Q3 2024, indicating improved financial performance. |
| Net Loss (YTD Sep 2025) | $66.409M | Decreased from $109.124M in YTD Sep 2024, showing a reduced overall loss. |
| Research and Development Expenses (YTD Sep 2025) | $53.864M | Significantly decreased from $92.845M in YTD Sep 2024, reflecting cost management. |
| Cash and Cash Equivalents (Sep 30, 2025) | $46.642M | Decreased from $58.279M at Dec 31, 2024, highlighting ongoing cash burn. |
| Accumulated Deficit (Sep 30, 2025) | $453.660M | Increased from $387.251M at Dec 31, 2024, indicating continued losses since inception. |
| Warrant Liability (Sep 30, 2025) | $17.914M | New non-current liability, reflecting recent public offerings and potential future dilution. |
| Common Shares Outstanding (Oct 31, 2025) | 70,703,639 | Increased from 36,310,713 shares at Dec 31, 2024, indicating significant dilution from equity raises. |
| Proceeds from Public Offerings (YTD Sep 2025) | $40.396M | Capital raised to fund operations, offsetting some of the cash burn. |
| SEC File Number | 001-40335 | Identifies the company's filing history with the SEC. |
| Central Index Key | 0001840439 | Unique identifier for the filer in the SEC system. |
| Net Loss (Q2 2025) | $55.2M | Increased from $45.1M in Q2 2024, reflecting higher operating expenses. |
| R&D Expenses (Q2 2025) | $47.3M | Up from $37.5M in Q2 2024, driven by clinical trial advancements for BMF-219 and BMF-500. |
| Gross Proceeds from Public Offering | $150.0M | Raised in July 2025, extending the company's cash runway for operations. |
| Revenue (Q2 2025) | 0 | Consistent with a clinical-stage biotechnology company, indicating no commercial products yet. |
| G&A Expenses (Q2 2025) | $8.0M | Increased from $7.0M in Q2 2024, supporting general corporate functions. |
Forward-Looking Statements
- {"claim":"Rainer M. Erdtmann will maintain a significant, passive stake in Biomea Fusion, Inc. for the foreseeable future.","entity":"Rainer M. Erdtmann","targetDate":"December 31, 2024","confidence":"medium"}
- {"claim":"FMR LLC will maintain a significant, passive ownership stake in Biomea Fusion, Inc. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
- {"claim":"Biomea Fusion, Inc. will continue to attract institutional investment due to its current ownership structure.","entity":"Biomea Fusion, Inc.","targetDate":"2024-08-09","confidence":"medium"}
- {"claim":"Other institutional investors may take a closer look at Biomea Fusion, potentially increasing trading volume.","entity":"Biomea Fusion, Inc.","targetDate":"Q1 2024","confidence":"medium"}
- {"claim":"Laurion Capital Management LP will maintain or slightly increase its stake in Biomea Fusion in the near term.","entity":"Laurion Capital Management LP","targetDate":"Q2 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Biomea Fusion, Inc. (BMEA)?
Biomea Fusion, Inc. has 38 recent SEC filings from Jan 2024 to Nov 2025, including 19 8-K, 6 10-Q, 6 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BMEA filings?
Across 38 filings, the sentiment breakdown is: 2 bullish, 34 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Biomea Fusion, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Biomea Fusion, Inc. (BMEA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Biomea Fusion, Inc.?
Key financial highlights from Biomea Fusion, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BMEA?
The investment thesis for BMEA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Biomea Fusion, Inc.?
Key executives identified across Biomea Fusion, Inc.'s filings include Dr. Michael J. Kelly, Thomas L. Jenkins, Dr. David R. Parkinson, Thomas Butler, Michael J. M. Hitchcock, Ph.D. and 3 others.
What are the main risk factors for Biomea Fusion, Inc. stock?
Of BMEA's 31 assessed filings, 2 were flagged high-risk, 10 medium-risk, and 19 low-risk.
What are recent predictions and forward guidance from Biomea Fusion, Inc.?
Recent forward-looking statements from Biomea Fusion, Inc. include guidance on {"claim":"Rainer M. Erdtmann will maintain a significant, passive stake in Biomea Fusion, Inc. for the foreseeable futur and 4 other predictions.